- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04525547
Safety and Effectiveness of Nintedanib in Korean Patients
A Regulatory Required Non-interventional Study to Monitor the Safety and Effectiveness of Ofev(Nintedanib 150mg/100mg BID) in Korean Patients
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of, 49201
- Dong-A University Hospital
-
Chungcheongbuk-do, Korea, Republic of, 28644
- Chungbuk National University Hospital
-
Chungcheongnam-do, Korea, Republic of, 31151
- Soonchunhyang University Cheonan Hospital
-
Daegu, Korea, Republic of, 42601
- Keimyung University Dongsan Hospital
-
Gwangju, Korea, Republic of, 61469
- Chonnam National University Hospital
-
Gyeonggi-do, Korea, Republic of, 13620
- Seoul National University Bundang Hospital
-
Gyeonggi-do, Korea, Republic of, 10380
- Inje University Ilsan Paik Hospital
-
Gyeonggi-do, Korea, Republic of, 67924
- Myongji Hospital
-
Gyeongsangnam-do, Korea, Republic of, 50612
- Pusan National University Yangsan Hospital
-
Gyeongsangnam-do, Korea, Republic of, 51472
- Gyeongsang National University Changwon Hospital
-
Jeju-do, Korea, Republic of, 63241
- Jeju National University Hospital
-
Jeollabuk-do, Korea, Republic of, 54538
- Wonkwang Univertisy Hospital
-
Jeollabuk-do, Korea, Republic of, 54907
- Jeonbuk National University Hospital
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 03722
- Severance Hospital
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 05278
- Kyung Hee University Hospital at Gangdong
-
Seoul, Korea, Republic of, 02447
- Kyunghee University Medical Center
-
Seoul, Korea, Republic of, 04763
- Hanyang University Medical Center
-
Seoul, Korea, Republic of, 06591
- Catholic University of Korea Seoul St. Mary's Hospital
-
Ulsan, Korea, Republic of, 44033
- Ulsan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
- Patients diagnosed with idiopathic pulmonary fibrosis
- (or) Patients diagnosed with systemic sclerosis associated interstitial lung disease
- (or) patients diagnosed with chronic fibrosing ILD with a progressive phenotype
Description
Inclusion Criteria:
- Patients who have been started on Ofev in accordance with the approved label in Korea
- Patients who have signed on the data release consent form
Exclusion Criteria:
Patients for whom nintedanib is contraindicated according local label of Ofev
- Patients with known hypersensitivity to Ofev, peanut or soya, or to any of the excipients
- Women who are pregnant or nursing
- Patients with moderate(Child pugh B) and severe(Child Pugh c) hepatic impairment
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ofev treatment
Korean patients diagnosed with idiopathic pulmonary fibrosis, systemic sclerosis associated interstitial lung disease or chronic fibrosing interstitial lung diseases with a progressive phenotype receiving Ofev (nintedanib 150milligrams (mg)/100mg twice a day (BID))
|
Nintedanib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Adverse Events Who Took at Least One Dose of Ofev
Time Frame: Up to 24 weeks.
|
Number of patients with adverse events who took at least one dose of Ofev is presented.
|
Up to 24 weeks.
|
Change From Baseline in Forced Vital Capacity) (FVC) (mL) After 12 Weeks of Treatment
Time Frame: At baseline and at week 12.
|
Change from baseline in Forced Vital Capacity) (FVC) (mL) after 12 weeks of treatment is presented. Forced vital capacity (FVC) is part of a pulmonary function test that assesses the lung function. It is defined as the greatest volume of air that can be expelled when a person performs a rapid, forced exhalation. |
At baseline and at week 12.
|
Change From Baseline in Forced Vital Capacity) (FVC) (mL) After 24 Weeks of Treatment
Time Frame: At baseline and at week 24.
|
Change from baseline in Forced Vital Capacity) (FVC) (mL) after 24 weeks of treatment is presented. Forced vital capacity (FVC) is part of a pulmonary function test that assesses the lung function. It is defined as the greatest volume of air that can be expelled when a person performs a rapid, forced exhalation. |
At baseline and at week 24.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1199-0417
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Nintedanib
-
Boehringer IngelheimCompletedCarcinoma, HepatocellularJapan
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedHealthyUnited Kingdom
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruiting
-
Wake Forest University Health SciencesBoehringer IngelheimTerminated
-
Boehringer IngelheimCompletedIdiopathic Pulmonary FibrosisSpain, Korea, Republic of, Belgium, Czechia, Australia, Germany, United Kingdom, United States, France, Finland, Japan, Poland, Hungary
-
Boehringer IngelheimApproved for marketingIdiopathic Pulmonary FibrosisUnited States
-
Boehringer IngelheimActive, not recruitingLung Diseases, InterstitialUnited States, Spain, United Kingdom, Canada, Finland, Norway, Italy, Argentina, Belgium, Brazil, Czechia, France, Greece, Mexico, Poland, Germany, Portugal
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
Boehringer IngelheimNo longer availableIdiopathic Pulmonary FibrosisBrazil